Skip to main content
SpringerLink
Log in

Studi farmacoeconomici: revisione della letteratura

  • Chapter
Costi sociali e aspetti farmacoeconomici

Part of the book series: Aspetti psico-sociali della sclerosi multipla ((APSSM,volume 4))

  • 220 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 24.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. Holloway RG (1996) Cost-effectiveness analysis: what is it and how will it influence neurology. Ann Neurol 39(6):818–823

    Article  CAS  PubMed  Google Scholar 

  2. Richards RG, Sampson FC, Beard SM, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6(10):3–73

    Google Scholar 

  3. Clegg A, Bryant J, Milne R (2000) Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 4(9):i–iv, 1–101

    CAS  Google Scholar 

  4. Parkin D, McNamee P, Jacoby A et al (1998) A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 2(4):3–54

    Google Scholar 

  5. Parkin D, Jacoby A, McNamee P et al (2000) Treatment of multiple sclerosis with interferon b: an appraisal of cost-effectiveness and quality of life. JNNP 68(2):144–149

    CAS  Google Scholar 

  6. Vickrey BG, Hays RD, Harooni R et al (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4(3):187–206

    Article  CAS  PubMed  Google Scholar 

  7. Williams A (1995) The role of the EUROQOL instrument in QALY calculations. Centre for Health Economics, University of York, York

    Google Scholar 

  8. Forbes RB, Lees A, Waugh N, Swingler RJ (1999) Population-based cost utility study of interferon beta 1b in secondary progressive multiple sclerosis. BMJ 319(7224):1529–1533

    CAS  PubMed  Google Scholar 

  9. European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497

    Google Scholar 

  10. Nuijten MJ, Hutton J (2002) Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 5(1):44–54

    Article  PubMed  Google Scholar 

  11. Brown MG, Murray TJ, Sketris IS et al (2000) Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care 16(3):751–767

    CAS  PubMed  Google Scholar 

  12. The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661

    Google Scholar 

  13. Sketris IS, Brown MG, Murray TJ et al (1996) Drug therapy in multiple sclerosis. A study of Nova Scotia Senior citizens. Clin Therapeutics 18(2):303–318

    CAS  Google Scholar 

  14. Kendrick M, Johnson KI (2000) Long-term treatment of multiple sclerosis with interferon-â may be cost effective. Pharmacoeconomics 18(1):45–53

    CAS  PubMed  Google Scholar 

  15. Murphy N, Confavreux C, Haas J et al (1998) Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13:607–622

    Google Scholar 

  16. Phillips CJ, Gilmour L, Gale R, Palmer M (2001) A cost utility model of interferon beta 1b in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:35–50

    Google Scholar 

  17. Kobelt G, Jonsson L, Henriksson F et al (2000) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 16(3):768–780

    CAS  PubMed  Google Scholar 

  18. Kobelt G, Jonsson L, Miltenburger C, Jonsson B (2002) Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health care 18(1):127–138

    PubMed  Google Scholar 

  19. Henriksson F, Jonsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13:597–606

    Google Scholar 

  20. Weinshenker BG, Brass B, Rice GP et al (1989) The natural history of multiple sclerosis: A geographically based study, I: Clinical course and disability. Brain 112(6):133–146

    PubMed  Google Scholar 

  21. Weinshenker BG, rice GP. Noseworthy JH et al (1991) The natural history of multiple sclerosis: A geographically based study, II: Multivariate analysis of predictive factors and models of outcome. Brain 114(2):1045–1056

    PubMed  Google Scholar 

  22. Nicholson T, Milne R (1996) Copolymer 1 in relapsing-remitting multiple sclerosis. (Report n. 63) Wessex Institute for Health Research and Development. Development and Evaluation Committee, Southampton

    Google Scholar 

  23. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276

    CAS  PubMed  Google Scholar 

  24. Bose U, Ladkani D, Burrell A, Sharief M (2001) Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ 4:207–219

    Google Scholar 

  25. Touchette DR, Durgin TL, Wankle LA, Goodkin DE (2003) A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in secondary progressive or progressive-relapsing multiple sclerosis. Clin Therapeutics 25(2):611–634

    Google Scholar 

  26. Rubio-Terres C, Aristegui RI, Medina Redondo F, Izquierdo A (2003) Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm Hosp 27(3):159–165

    CAS  PubMed  Google Scholar 

  27. Hollendorf DA, Jilinskaia E, Oleen-Burkey M (2002) Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 8(6):469–476

    Google Scholar 

  28. Chilcott J, McCabe C, Tappenden P et al (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326(7388):522–527

    Article  PubMed  Google Scholar 

  29. Patzold U, Pocklington PR (1982) Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976–80. Acta Neurol Scand 65(4):248–266

    CAS  PubMed  Google Scholar 

  30. Kobelt G, Lindgren P, Parkin D et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Scandinavian working papers in Economics 2000 (http://swopec.hhs.se/hastef/papers/hastef0398.pdf)

    Google Scholar 

Download references

Authors
  1. M.P. Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Portaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Italia

About this chapter

Cite this chapter

Amato, M., Portaccio, E. (2005). Studi farmacoeconomici: revisione della letteratura. In: Costi sociali e aspetti farmacoeconomici. Aspetti psico-sociali della sclerosi multipla, vol 4. Springer, Milano. https://doi.org/10.1007/88-470-0401-2_6

Download citation

  • DOI: https://doi.org/10.1007/88-470-0401-2_6

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0327-9

  • Online ISBN: 978-88-470-0401-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation